Hao‐Xiang Wu

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center · ORCID：0000-0001-6719-7133

发表论文 58 篇 · 总被引 2210 次 · h-index 25

代表论文

• Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response (2022 · Genome Medicine · 被引 289)
• Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1–Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis (2022 · Journal of Clinical Oncology · 被引 76)
• Development of antibody‐drug conjugates in cancer: Overview and prospects (2023 · 癌症：英文版 · 被引 73)
• MFSD2A potentiates gastric cancer response to anti‐PD‐1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response (2023 · 癌症：英文版 · 被引 43)
• Transplantation for EASL-CLIF and APASL acute-on-chronic liver failure (ACLF) patients: The TEA cohort to evaluate long-term post-Transplant outcomes (2022 · EClinicalMedicine · 被引 37)
• Aggregation‐Induced Emission (AIE) and Magnetic Resonance Imaging Characteristics for Targeted and Image‐Guided siRNA Therapy of Hepatocellular Carcinoma (2022 · Advanced Healthcare Materials · 被引 26)